
Chinese Biopharma Firms Chase Hong Kong IPO, After Duality's Sizzling Debut
The company enjoys a big share of China's anti-tetanus market but is looking to diversify into antidotes for rabies and snake bites to drive future growth Key Takeaways: The company relies on human tetanus jabs for more than 90% of its revenue, but …